SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
AstraZeneca PLC Divests Yet Another Drug, This Time to Sanofi for $300 Million
July 27, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Policy
EXCLUSIVE: Ironwood, AstraZeneca PLC IBS-C Drug Will File in China Next Year, CEO Tells BioSpace
July 9, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Deals
AstraZeneca PLC Offloads Crohn’s Disease Drug for $215 Million
July 9, 2015
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
GlaxoSmithKline Will Receive $140B+ Bid in Q4, From Suitors Including Pfizer and AstraZeneca PLC: Poll
July 1, 2015
 · 
2 min read
Business
AstraZeneca PLC’s Antibiotics Alums Emerge at Biotech Spinout Entasis Therapeutics
July 1, 2015
 · 
2 min read
Business
Another Senior AstraZeneca PLC Executive Departs to Helm Rival Company
June 24, 2015
 · 
3 min read
Business
Ex-AstraZeneca PLC CMO Takes Helm at Tiny Syndax
June 15, 2015
 · 
4 min read
Biotech Bay
BioSpace Temperature Poll: After AstraZeneca PLC CMO Abruptly Quits, Where Could He Be Headed?
June 11, 2015
 · 
1 min read
Business
BREAKING: AstraZeneca PLC’s CMO Abruptly Jumps Ship to Unnamed Biotech
June 10, 2015
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
June 26, 2026
 · 
10 min read
Press Releases
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
 · 
7 min read
Press Releases
AstraZeneca Joins ZERO Prostate Cancer’s Historic ‘Blitz the Barriers’ Initiative as a Founding Partner
June 15, 2026
 · 
3 min read
Press Releases
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 14, 2026
 · 
19 min read
Press Releases
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 8, 2026
 · 
7 min read
Press Releases
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
June 3, 2026
 · 
4 min read
Press Releases
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 1, 2026
 · 
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 29, 2026
 · 
19 min read
Press Releases
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 24, 2026
 · 
19 min read
Press Releases
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
May 24, 2026
 · 
19 min read
Load More